Sutton Wealth Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sutton Wealth Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5	Closed	-$1K	–	1658
2022 Q3	$1K	Buy	+5	New	+$954	﹤0.01%	1296
2022 Q2	–	Sell	-8	Closed	-$1.31K	–	1640
2022 Q1	$1.31K	Buy	+8	New	+$1.22K	﹤0.01%	1274
2019 Q2	–	Sell	-7	Closed	-$654	–	1164
2019 Q1	$654	Sell	7 -134	-95%	-$11.2K	﹤0.01%	1139
2018 Q4	$10.3K	Buy	141 +1	+0.7%	+$77	0.01%	738
2018 Q3	$12.3K	Buy	140 +3	+2%	+$302	0.01%	747
2018 Q2	$13.5K	Hold	137	–	–	0.01%	748
2018 Q1	$16.3K	Sell	137 -69	-33%	-$8.89K	0.01%	649
2017 Q4	$26.2K	Buy	206 +69	+50%	+$8.67K	0.02%	458
2017 Q3	$16.1K	Hold	137	–	–	0.01%	615
2017 Q2	$10.9K	Buy	+137	New	+$8.76K	0.01%	727
2016 Q4	–	Sell	-112	Closed	-$7.59K	–	1060
2016 Q3	$7.59K	Buy	+112	New	+$7.9K	0.01%	731
2016 Q2	–	Sell	-170	Closed	-$10.7K	–	1024
2016 Q1	$10.7K	Buy	+170	New	+$11.3K	0.01%	598

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sutton Wealth Advisors's ALNY Position: Q4 2022 in Review

Sutton Wealth Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2022, closing a stake of 5 shares — an estimated $1K sold.

Sutton Wealth Advisors first reported a position in ALNY in Q1 2016 and held it in 12 quarters. The position peaked at $26.2K in Q4 2017. 487 funds tracked by Wall St. Rank hold ALNY as of Q4 2022.

Sutton Wealth Advisors reported no remaining Alnylam Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Sutton Wealth Advisors sold 5 Alnylam Pharmaceuticals shares in Q4 2022, an estimated $1K.
Sutton Wealth Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2016 and held it in 12 quarters.
Sutton Wealth Advisors's Alnylam Pharmaceuticals position peaked at $26.2K in Q4 2017.
487 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2022.

Based on Sutton Wealth Advisors's 13F filing for Q4 2022, filed 7 Nov 2023.